{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:55:48Z","timestamp":1778694948552,"version":"3.51.4"},"reference-count":66,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some progress early after initial response. To investigate this, we examined 44 whole-genome and whole-exome sequencing data samples from 34 patients with t(11;14) MM treated with venetoclax. The presence of mutations in the RAS pathway was strongly associated with shortened progression-free survival (PFS) and was validated in an independent cohort of 21 patients with MM. The presence of 1q gain was also associated with shorter PFS in patients without RAS mutations. In 10 patients with paired prevenetoclax and postvenetoclax treatment samples, postvenetoclax progression was recurrently driven by the selection of genomic events in the BCL2\/MCL1 and RAS pathways and of high-risk features (eg, loss of TP53 and CDKN2C). Overall, our study shows that comprehensive genomic profiling can identify most mechanisms underlying resistance to BCL2 inhibition in t(11;14)(CCND1;IGH) MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029996","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:16:06Z","timestamp":1767374166000},"page":"1598-1610","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(\n                    <i>CCND1<\/i>\n                    ;\n                    <i>IGH<\/i>\n                    )"],"prefix":"10.1182","volume":"147","author":[{"given":"Marcella","family":"Kaddoura","sequence":"first","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[{"name":"4Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"5Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suganti","family":"Shivaram","sequence":"additional","affiliation":[{"name":"6Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Tang","sequence":"additional","affiliation":[{"name":"6Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca W.","family":"Owens","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Sevcikova","sequence":"additional","affiliation":[{"name":"4Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"5Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-0340","authenticated-orcid":false,"given":"Rodrigo","family":"Fonseca","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-6847","authenticated-orcid":false,"given":"Michael","family":"Durante","sequence":"additional","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-7756","authenticated-orcid":false,"given":"Yuan X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Xin","family":"Shi","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Matulis","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"4Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic"},{"name":"5Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-4830","authenticated-orcid":false,"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[{"name":"6Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"19","key":"2026040211215571400_bib1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2026040211215571400_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2026040211215571400_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"2026040211215571400_bib4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2026040211215571400_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"2026040211215571400_bib6","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2026040211215571400_bib7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2026040211215571400_bib8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res"},{"issue":"6","key":"2026040211215571400_bib9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2026040211215571400_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2026040211215571400_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00019","article-title":"Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach","volume":"2018","author":"Lagan\u00e0","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"2026040211215571400_bib12","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2026040211215571400_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2026040211215571400_bib14","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2026040211215571400_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41588-025-02292-1","article-title":"Temporal genomic dynamics shape clinical trajectory in multiple myeloma","volume":"57","author":"Maura","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"2026040211215571400_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood.2023020276","article-title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","volume":"143","author":"Leblay","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2026040211215571400_bib17","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","article-title":"Functional impact of genomic complexity on the transcriptome of multiple myeloma","volume":"27","author":"Ziccheddu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026040211215571400_bib18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026040211215571400_bib19","doi-asserted-by":"crossref","first-page":"20406207231155028","DOI":"10.1177\/20406207231155028","article-title":"Efficacy and safety of venetoclax-based regimens for the treatment of relapsed\/refractory multiple myeloma: a systemic review and meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"26","key":"2026040211215571400_bib20","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026040211215571400_bib21","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.clml.2019.09.033","article-title":"Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients","volume":"19","author":"Maity","year":"2019","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"24","key":"2026040211215571400_bib22","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"2026040211215571400_bib23","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2022017341","article-title":"Mechanisms of resistance to venetoclax","volume":"140","author":"Condoluci","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2026040211215571400_bib24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026040211215571400_bib25","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2026040211215571400_bib26","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026040211215571400_bib27","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026040211215571400_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol Chem"},{"issue":"12","key":"2026040211215571400_bib65","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"32","key":"2026040211215571400_bib66","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026040211215571400_bib29","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026040211215571400_bib30","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1016\/j.clml.2021.05.001","article-title":"Dual primary IGH translocations in multiple myeloma: a novel finding","volume":"21","author":"Ravindran","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026040211215571400_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12308-025-00626-w","article-title":"A rare case of multiple myeloma with double translocations: t(11;14) and t(14;16)","volume":"18","author":"Meseha","year":"2025","journal-title":"J Hematop"},{"issue":"3","key":"2026040211215571400_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1078-0432.CCR-23-1045","article-title":"Impact of rare structural variant events in newly diagnosed multiple myeloma","volume":"30","author":"Chojnacka","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026040211215571400_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"issue":"5","key":"2026040211215571400_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"2026040211215571400_bib35","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2026040211215571400_bib36","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.cellsig.2008.06.002","article-title":"WNK2 modulates MEK1 activity through the Rho GTPase pathway","volume":"20","author":"Moniz","year":"2008","journal-title":"Cell Signal"},{"issue":"4779","key":"2026040211215571400_bib37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.3490692","article-title":"A common mechanism of chromosomal translocation in T- and B-cell neoplasia","volume":"234","author":"Finger","year":"1986","journal-title":"Science"},{"issue":"3","key":"2026040211215571400_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0092-8674(85)80070-2","article-title":"Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18","volume":"41","author":"Bakhshi","year":"1985","journal-title":"Cell"},{"issue":"21","key":"2026040211215571400_bib39","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.82.21.7439","article-title":"Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18","volume":"82","author":"Cleary","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026040211215571400_bib40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386","article-title":"Molecular thanatopsis: a discourse on the BCL2 family and cell death","volume":"88","author":"Yang","year":"1996","journal-title":"Blood"},{"issue":"6189","key":"2026040211215571400_bib41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"issue":"16","key":"2026040211215571400_bib42","first-page":"2196","article-title":"The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026040211215571400_bib43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2026040211215571400_bib44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2024-201056","article-title":"Convergent evolution towards CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma","volume":"144","author":"Diamond","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026040211215571400_bib45","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2026040211215571400_bib46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.2024024299","article-title":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","volume":"144","author":"Cirrincione","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026040211215571400_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026040211215571400_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2026040211215571400_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"20","key":"2026040211215571400_bib50","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/bloodadvances.2020003826","article-title":"Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma","volume":"5","author":"Bolomsky","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"2026040211215571400_bib51","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026040211215571400_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2026040211215571400_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2026040211215571400_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-025-01215-x","article-title":"Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention","volume":"15","author":"Fonseca","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026040211215571400_bib55","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Algar\u00edn","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2026040211215571400_bib56","first-page":"2930","article-title":"Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma","volume":"109","author":"Flanagan","year":"2024","journal-title":"Haematologica"},{"issue":"20","key":"2026040211215571400_bib57","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2026040211215571400_bib58","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","article-title":"Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2026040211215571400_bib59","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.2023021581","article-title":"A p53 score derived from TP53 CRISPR\/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics","volume":"143","author":"Durand","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026040211215571400_bib60","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","article-title":"Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers","volume":"42","author":"Diepstraten","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"2026040211215571400_bib61","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2026040211215571400_bib62","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax resistance in acute myeloid leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026040211215571400_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41698-022-00315-2","article-title":"Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)","volume":"6","author":"Nguyen","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"2026040211215571400_bib64","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/14\/1598\/2511757\/blood_bld-2025-029996-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/14\/1598\/2511757\/blood_bld-2025-029996-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:22:15Z","timestamp":1775143335000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/14\/1598\/557587\/Genomic-mechanisms-of-resistance-to-venetoclax-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":66,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029996","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,2]]},"published":{"date-parts":[[2026,4,2]]}}}